Abstract
Jinhuang Ointment combined with conventional therapy significantly improves joint pain and swelling, accelerates symptom relief, and exhibits particular efficacy in swelling reduction, without increasing safety risks. Its multi-component, multi-target mechanism provides a potential explanation for the clinical efficacy observed, thereby supporting the need for higher-quality studies to further verify its application value.
Introduction
Acute gouty arthritis (AGA) is characterized by intense inflammatory pain resulting from monosodium urate crystal deposition. While non-steroidal anti-inflammatory drugs (NSAIDs) like celecoxib are standard first-line treatments, they are often limited by a "toxicity ceiling," where higher doses increase the risk of gastrointestinal, renal, and cardiovascular complications. This study evaluates Jinhuang Ointment—a traditional Chinese medicine (TCM) formula—as a topical adjunct to bridge the gap in localized symptom management.
Methodology
This retrospective cohort study analyzed 104 patients treated for AGA between July 2023 and June 2024. Participants were categorized into three distinct treatment arms:
- Control Group (n=35): Standard Western therapy (oral celecoxib, hydration, and low-purine diet).
- Treatment Group 1 (T1, n=35): Standard therapy plus topical diclofenac diethylamine emulsion (a conventional Western NSAID).
- Treatment Group 2 (T2, n=34): Standard therapy plus Jinhuang Ointment.
Outcomes were assessed over seven days, focusing on the Visual Analog Scale (VAS) for pain, joint swelling, mobility, and systemic inflammatory markers like C-reactive protein (CRP).
Key Insights
The Speed of Recovery
A critical finding was the reduction in time required to achieve significant pain relief (defined as a VAS score < 3). The Jinhuang Ointment group (T2) demonstrated a significantly faster recovery trajectory compared to both the standard care and the topical NSAID groups.
Superiority in Swelling Reduction
While both topical interventions improved outcomes, the Jinhuang Ointment group showed a statistically significant advantage in reducing joint swelling over the topical NSAID group. This suggests that the herbal components may uniquely enhance local microcirculation and lymphatic drainage, addressing the "symptom burden" more effectively than localized NSAIDs alone.
Clinical Outcomes
Pain Management
All groups showed improvement over the 7-day course; however, the T2 group achieved significantly lower VAS scores by Day 3 and Day 7 compared to the Control and T1 groups. This indicates that the multi-target pharmacology of the TCM formula—likely inhibiting the NF-κB and NLRP3 inflammasome pathways—provides superior localized anti-inflammatory action.
Inflammatory Markers and Safety
Both T1 and T2 groups exhibited more pronounced decreases in CRP and Erythrocyte Sedimentation Rate (ESR) than the control. Notably, serum uric acid levels did not differ significantly between groups, confirming that the ointment's efficacy is derived from local anti-inflammatory properties rather than systemic metabolic changes. Safety profiles remained excellent, with only minor, self-resolving skin irritation or gastric discomfort reported across all cohorts.
Conclusion and Future Directions
Jinhuang Ointment serves as a safe and effective adjunct to conventional AGA therapy, offering faster pain relief and superior swelling reduction. While limited by its retrospective nature and sample size, this study provides a strong rationale for future large-scale, prospective randomized controlled trials to further validate these findings and explore the molecular mechanisms of its herbal components.
Summary updated